ERBB3 and cancer: Among the top three candidates for both gains and losses, CDKN2C gain, KIT loss, and GNAS loss were unique to GC cell lines, while ERBB3 gain, FBXW gain, and hypoxia-inducible factor 1a loss were also observed in other cancer types (Supplemental Fig. S2B).